125 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
focused on patients with relapsed and refractory multiple myeloma.
BMS will be responsible for the worldwide clinical development and commercialization … and royalties. EMD Serono will be responsible for the drug product and the clinical development and commercialization of this clinical development
8-K
EX-99.1
STRO
Sutro Biopharma Inc
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
myeloma. The last reported dose level was 3.0 mg/kg with dose escalation continuing.
BMS will be responsible for the worldwide clinical development … supply of the candidate and is eligible for milestones and royalties. EMD Serono will be responsible for the drug product and the clinical development
8-K
EX-99.1
STRO
Sutro Biopharma Inc
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
with relapsed and refractory multiple myeloma.
BMS will be responsible for the worldwide clinical development and commercialization of CC-99712 … Serono will be responsible for the drug product, clinical development and commercialization of this clinical development candidate.
24-Valent
8-K
EX-99.1
9diq6ge4
7 May 21
Business Highlights and 2021 Anticipated Milestones
7:00am
8-K
EX-99.1
fb5fkae
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
8-K
EX-99.1
4n13r
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
UPLOAD
jigh52wi8jw 7x5dc4gx
16 Nov 23
Letter from SEC
12:00am
8-K
EX-99.1
bywhc4ze o1
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
DRS
EX-10.9
4nb84ahyda3u 74t0rk
1 Jun 18
Draft registration statement
12:00am
UPLOAD
38v2egy2eeorer85
8 Oct 19
Letter from SEC
12:00am